The efflux transporter P-glycoprotein (ABCB1) acts at the blood-brain barrier (BBB) to restrict the distribution of many different drugs from blood to the brain. Previous data suggest an age-associated decrease in the expression and function of ABCB1 at the BBB. In the present study, we investigated the influence of age on the magnitude of an ABCB1-mediated drug-drug interaction (DDI) at the BBB.
Introduction
The blood-brain barrier (BBB) is a sophisticated anatomical structure which protects the brain from potentially harmful blood-borne substances [3] . This protective mechanism is enhanced by the expression of efflux transporters in the luminal (blood-facing) membrane of brain capillary endothelial cells [3] . These transporters belong to the adenosine triphosphate (ATP)-binding cassette (ABC) family and use the energy of ATP to translocate their substrates, against concentration gradients, from the endothelial cell into blood. The best characterized of these transporters is P-glycoprotein (ABC subfamily B, member 1, humans: ABCB1, rodents: Abcb1a). ABCB1 restricts the brain distribution of a multitude of different, structurally unrelated drugs and may be implicated in drug-drug interactions (DDIs) at the BBB [4] . In such ABCB1-mediated DDIs, concomitant administration of two drugs which are recognized by ABCB1 may result in the partial inhibition of ABCB1 transport activity at the BBB and increases in the brain distribution of one of these drugs, compared with the administration of one of these drugs alone. Transportermediated DDIs are of great concern in drug development as they may lead to central nervous system (CNS) adverse effects of drugs. Studies in mice have shown that genetic knockout of Abcb1a can result in dramatic increases in the brain distribution of drugs which are selective ABCB1 substrates (e.g. ivermectin, vinblastine, digoxin, cyclosporine A, loperamide) [5] [6] [7] . However, for drugs that are recognized by other efflux transporters, in addition to ABCB1, at the BBB, in particular breast cancer resistance protein (ABCG2), much smaller increases in brain distribution will be achieved when only ABCB1 is inhibited, as the other non-inhibited transporter(s) may compensate for the function of ABCB1 [8, 9] . According to current thinking, transporter-mediated DDIs are unlikely to occur in humans as most drugs are not expected to achieve high enough unbound plasma concentrations to lead to significant efflux transporter inhibition at the human BBB [10] . Transporter-mediated DDIs at the BBB occur in most cases without changes in drug plasma pharmacokinetics, so that drug concentrations in the brain need to be considered in order to assess such DDIs [11, 12] . Positron emission tomography (PET) is an imaging method which enables the non-invasive measurement of the distribution of radiolabelled drugs within the body. It has been used before to assess transporter-mediated DDIs in various organs, such as the brain [13] [14] [15] [16] and the liver [17] .
Disturbances in BBB integrity are involved in normal ageing and contribute to the onset and progression of neurological diseases [18] [19] [20] . There is evidence that ABCB1 expression at the BBB declines in healthy ageing and in Alzheimer's disease [21] [22] [23] . PET imaging with (R)-
verapamil can be used to measure non-invasively the function of ABCB1 at the human BBB [24, 25] . Results from PET studies suggest a moderate decrease in ABCB1 function at the human BBB with increasing age [26] [27] [28] [29] . We hypothesized that an age-associated reduction in ABCB1 expression and function at the BBB will lead to higher increases in the brain distribution of ABCB1-selective substrates, when ABCB1 is partially (incompletely) inhibited, which could result in an elevated risk of ABCB1-mediated DDIs at the BBB in elderly as compared with younger persons.
In the present study, we compared the effect of ABCB1 inhibition with the third-generation ABCB1 inhibitor tariquidar [30] [24] . The ABCB1 inhibitor tariquidar (AzaTrius Pharmaceuticals, Mumbai, India) was administered as an intravenous infusion over 30 min at a dose of 3 mg kg À1 body weight at the end of the first PET scan, 3 h before start of the second PET scan, as described previously [34] . Whole-brain grey matter, and the temporal lobe, parietal lobe, cerebellum and cingulate gyrus were outlined as regions of interest using the Hammersmith maximum probabilistic atlas of the human brain [32] . Total distribution volume (V T ), which equals the brain to plasma concentration ratio of radiotracer at steady state, as well as the rate constants describing the transfer of radiotracer across the BBB, were estimated using a standard two tissue-four rate constant (2T4K) compartment model ( Figure 1 ) [34] . The vascular volume fraction in the brain was included as a fitting parameter. To obtain a model-independent estimate of V T , Logan graphical analysis was performed [35] . Tariquidar plasma concentrations at the time of the second PET scan were determined using liquid chromatography tandem mass spectrometry [36] . From concentration-time curves of radioactivity in plasma, normalized to injected dose per body weight and expressed as standardized uptake value (SUV), the area under the curve (AUC) was calculated.
Statistical analysis
Our study was exploratory, so no sample size calculation was performed. All data are presented as mean ± standard deviation (SD). The Mann-Whitney U test was used for statistical comparisons of measurements in the young and elderly, and the Wilcoxon signed-rank test for comparison of outcome parameters within one group (scan 1 and scan 2). To assess correlations, the Spearman rank coefficient (r) was calculated. Statistical analysis was performed using Statistica 6.1 (StatSoft, Tulsa, OK, USA). Statistical significance was set at P < 0.05.
Results
Five young men (mean age: 26 ± 1 years) and five elderly men (mean age: 68 ± 6 years) were included in the study. There was no significant brain atrophy present on MRI scans, and the MMSE scores for the elderly group (30 ± 0.4) were within normal range. All volunteers were medication free at time of the PET study, except for one elderly volunteer, who was on stable medication with tamsulosin, an alpha-1 antagonist for the treatment of benign prostatic hyperplasia. In all subjects, (R)- Diagram of the two tissue-four rate constant (2T4K) compartment model used for the kinetic modelling of (R)-[ 11 C]verapamil PET data. C p is concentration of radiotracer in arterial plasma; C 1 and C 2 denote the radiotracer concentrations in the first and second brain tissue compartment. K 1 (ml (g*min)
À1 ) and k 2 , k 3 and k 4 (min À1 ) are first-order rate constants describing the transfer of radiotracer between the plasma, the first and the second brain tissue compartments. Total distribution volume (V T ) is calculated as (1 + (k 3 /k 4 ) * (K 1 /k 2 ) and corresponds to the brain to plasma concentration ratio of the radiotracer at steady state 0.70 ± 0.02, elderly: 0.77 ± 0.06; scan 2: young: 0.73 ± 0.06, elderly: 0.76 ± 0.03) ( Figure 2B ). As the main outcome parameter of (R)-[ 11 C]verapamil brain distribution, we chose V T , which equals the brain to plasma concentration ratio of radiotracer at steady state, and which was found in previous studies to be sensitive to ABCB1 inhibition [16, 25, 34] . In scan 1, (R)- (Table 1) . Similar results as in wholebrain grey matter were obtained for the other brain regions which had been selected based on previous studies to assess ABCB1 function at the BBB (Table 1 ) [26] . Other than V T , the influx rate constant of radioactivity from the plasma into the brain, K 1 , was significantly increased in the elderly but not in the young group following ABCB1 inhibition (Table 1) . Tariquidar plasma concentrations during scan 2 were not significantly different (P = 0.222) between the young (786 ± 178 nmol l À1 ) and the elderly (1116 ± 347 nmol l À1 ) group (Table 2 ). There was a significant positive correlation between the percentage change of (R)-[ 11 C]verapamil V T in scan 2 and tariquidar plasma concentrations in the elderly (r = 1.000, P = 0.017) but not in the young (r = À0.200, P = 0.783) group ( Figure 5) . In a subset of three young (subjects 3, 4 and 5) and three elderly (subjects 8, 9 and 10) subjects, in whom tariquidar plasma concentrations at the time of the PET scans were comparable (Table 2) , there was a deviation)] calculated from the two tissue-four rate constant model in whole-brain grey matter for young and elderly subjects before (scan 1) and after (scan 2) ABCB1 inhibition (A) and percent change of V T (mean ± standard deviation) in response to P-glycoprotein inhibition (B). *P < 0.05, Mann-Whitney U test or Wilcoxon signed-rank test significantly greater change (P = 0.025, Student's t-test) in (R)-[ 11 C]verapamil V T in scan 2 in elderly (+28 ± 9%) than in young (À6 ± 14%) subjects.
Discussion
To our knowledge, this was the first study to examine directly the influence of age on the magnitude of an ABCB1-mediated DDI at the human BBB. As the model ABCB1 substrate, we used (R)-[ 11 C]verapamil, which was shown to be selectively transported by ABCB1, and not by ABCG2, at the BBB [37] . As the model ABCB1 inhibitor, we used the nonmarketed third-generation ABCB1 inhibitor tariquidar [30] , which inhibits ABCB1 at the human BBB effectively, resulting in up to fourfold increases in (R)-[ 11 C]verapamil brain uptake [25] . Tariquidar also inhibits ABCG2, but at considerably higher concentrations than needed for ABCB1 inhibition [9, 38] . In contrast to previous studies, in which we had administered tariquidar at doses up to 8 mg kg À1 [16, 25] , in the present study we administered only a low dose of tariquidar (3 mg kg À1 ) to achieve incomplete inhibition of ABCB1 at the BBB. Incomplete ABCB1 inhibition is a more realistic scenario for the clinic than complete inhibition, as clinically used drugs are not expected to lead to complete ABCB1 inhibition at the human BBB at clinically relevant plasma concentrations. In baseline scans without ABCB1 inhibition, we failed to detect significant differences in (R)-[ 11 C]verapamil V T values in the small sample of young and elderly subjects investigated in the present study ( Figure 3A ). This stands in contrast with previous (R)-
verapamil PET studies, conducted without administration of an ABCB1 inhibitor, which found moderately increased V T values (i.e. by 15-18%) in the brains of elderly subjects as compared with young subjects [26] [27] [28] . Our failure to reveal differences in ABCB1 function in baseline scans may have been related to the limited sensitivity of high-affinity ABCB1 substrates such as (R)-[ 11 C]verapamil to detect moderate changes in ABCB1 expression at the BBB. This has been attributed to the fact that ABCB1 is a high-capacity transporter, which is able to compensate functionally for moderate (<50%) decreases in its expression so that the brain distribution of ABCB1 substrates may remain unchanged [10, 39] . This phenomenon is, in fact, similar to the functional interplay between ABCB1 and ABCG2 at the BBB, resulting in only very small increases in the brain distribution of dual ABCB1/ABCG2 substrates, when ABCB1 alone is inhibited [9] . It has been estimated that the BBB needs to be depleted by more than 90% of ABCB1 to result in large (>2-fold) increases in the CNS penetration of ABCB1 substrates [10] . In agreement with this, we previously found that the brain distribution of (R)-
verapamil was increased by only 1.5-fold in heterozygous Abcb1a knockout mice, which have a 50% reduction in Abcb1a density at the BBB as compared with wild-type mice, whereas a 3.9-fold increase in (R)-
brain distribution was observed in homozygous Abcb1a knockout mice, which completely lack Abcb1a at the BBB [39] . Our previous results indicate that partial inhibition of ABCB1 increases the sensitivity of (R)-[ 11 C]verapamil to measure changes in ABCB1 function at the BBB [40, 41] .
In line with this, we found that, following ABCB1 inhibition, (R)-[ 11 C]verapamil V T values were significantly higher in elderly than in young subjects ( Figure 3A) . Despite the small sample size of our study, remarkably clear differences could be detected between the two groups. Tariquidar plasma concentrations at the time of the PET scans ranged from 601 nmol l À1 to 1554 nmol l À1 (Table 2) , which was below the previously determined in vivo halfmaximal effect concentration of tariquidar to enhance the brain uptake of (R)-[ 11 C]verapamil in young healthy volunteers (2248 nmol l À1 ) [25] . In two elderly subjects, tariquidar plasma concentrations were higher than in the young group (Table 2) . When comparing only subjects with similar tariquidar plasma concentrations (n = 3 per group), (R)-[ 11 C]verapamil V T increases in scan 2 were still significantly higher in the elderly group, suggesting that the observed group differences were not caused by differences in tariquidar plasma concentrations. The significantly higher increases in (R)-[ 11 C]verapamil brain distribution following partial ABCB1 inhibition found in elderly as compared with young subjects ( Figure 3B ) may have been caused by lower expression levels of ABCB1 in the brain capillaries of elderly persons [22] . The observed differences between elderly and young subjects are expected to disappear in the case of complete ABCB1 inhibition at the BBB; however, this is unlikely to occur in the clinic. Our data provide the first evidence for an increased risk of ABCB1-mediated DDIs at the BBB in elderly persons, which is of clinical relevance as elderly persons often take several different drugs on a regular basis [42] . Our results suggest that particular caution is warranted in the elderly, when coadministering drugs which inhibit ABCB1 (e.g. cyclosporine A or quinidine) with ABCB1 substrates, to avoid the occurrence of CNS adverse effects. This is unlikely to be relevant for drugs which are transported by other efflux Figure 4 Axial planes of standardized uptake value (SUV) positron emission tomography average images (0-40 min) for young and elderly subjects before (baseline) and after P-glycoprotein (ABCB1) inhibition
Influence of age on ABCB1-mediated DDI at the BBB Table 1 Modelling outcome parameters for different brain regions (8) 0.06 ± 0.02 (7) 0.05 ± 0.01 (7) 0.06 ± 0.02 (13) 0.06 ± 0.02 (14) 0.07 ± 0.03 (12) 0.06 ± 0.01 (19) 0.06 ± 0.01 (13) 0.05 ± 0.01 (6) 0.07 ± 0.02 (10) (2) 0.78 ± 0.11 (2) 0.80 ± 0.17 (3) 0.81 ± 0.10 (4) 0.81 ± 0.17 (2) 0.76 ± 0.11 (6) 0.85 ± 0.21 (4) 0.79 ± 0.10 (2) 0.80 ± 0.18 (1) (1) 1.07 ± 0.15 (0) * Outcome parameters are given as mean ± standard deviation (n = 5 per group). The value in parentheses represents the precision of parameter estimates (expressed as their coefficient of variation as a percentage), averaged over the study subjects
transporters at the BBB, in addition to ABCB1, such as dual ABCB1/ABCG2 substrates. The ABCB1-mediated DDI risk may be increased further in certain patient groups, in whom ABCB1 density at the BBB is reduced. For example, it has been shown that, in addition to several other changes occurring at the BBB [18] , the expression of ABCB1 is reduced at the BBB of patients with Alzheimer's disease [21] . In the present study, a model ABCB1 substrate was used at subtherapeutic doses (<20 μg) in combination with a potent, experimental ABCB1 inhibitor. Further studies, with larger sample sizes, including both male and female subjects [26] , are needed to find out the extent to which our results are also valid for clinically relevant combinations of ABCB1-substrate drugs and (less potent) ABCB1-inhibiting drugs, ideally used at clinical doses. A limitation of the present study was the relatively small number of subjects. Inclusion of a greater number of subjects into our study was hampered by our complex study protocol, involving two consecutive PET scans, with arterial blood sampling and intravenous infusion of tariquidar, and also by the limited availability of tariquidar for clinical use. Another limitation of our study was that we did not measure cerebral blood flow (CBF) in study participants. It has been suggested that the brain distribution of [
11 C]verapamil is dependent on CBF, and that [ 11 C] verapamil K 1 needs to be normalized to CBF to measure ABCB1 function at the BBB [43] . However, it appears unlikely that the age-associated differences in (R)-[ 11 C]verapamil brain distribution following ABCB1 inhibition observed in our study were caused by a higher CBF in the elderly, as CBF does not increase with age [44] . In addition, tariquidar administration does not lead to changes in CBF [15] .
In conclusion, we found significantly higher increases in the brain distribution of the model ABCB1 substrate (R)- [ 11 C]verapamil following partial ABCB1 inhibition in elderly vs. young subjects. This confirms previous findings of reduced ABCB1 expression/function at the BBB of the elderly and provides the first evidence of an increased risk for ABCB1-mediated DDIs at the BBB in elderly persons. The results of our study need to be confirmed in larger cohorts of subjects and need to be extended to other, clinically relevant combinations of ABCB1 substrates and inhibitors.
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